GSK NRT segment smokin’
This article was originally published in The Tan Sheet
Executive Summary
Nicotine replacement therapy sales advanced 14% "with all regions contributing to growth" to lead 2% OTC segment increase in the second quarter, GSK announces July 27. The firm is looking to future OTC weight-loss drug Xenical, which it acquired from Roche July 19 for $100 mil., to mirror success of smoking cessation products. Consumer Healthcare sales reached $1.44 bil., a 4% increase compared to the year-ago period; domestic sales were flat, although international sales rose 9% and European markets advanced 4%...